Reimbursement of high cost drugs the Polish experience
|
|
- Shon Hunter
- 6 years ago
- Views:
Transcription
1 Reimbursement of high cost drugs the Polish experience 1. Poland and Polish health care system 2. AHTAPol tasks and activities Iga Lipska, M.D. Deputy Director Bogusława Osińska, M.D. Chief Specialist, HTA Department Agency for Health Technology Assessment in Poland AHTAPol 3. Reimbursement high-cost drugs by NHF in Poland therapeutical programs 4. NHF, AHTAPol: challenges and future developments Poland Polish health care system Centralised Health insurance system - taxes National Health Fund (NHF) 16 regional branches NHF concludes contracts with health service providers NHF budget for 2009 is 56,8 billion PLN (14 billion EURO) Drug reimbursement - 7,3 billion PLN (12,9%) Therapeutic drug programs - 1,3 billion PLN (2%) Introduction a new drug A registration of medicinal product (EMEA, URPL) A pharmaceutical company Reimbursement criteria: Reimbursement submission form MoH A pharmaceutical company MoH (Drug Management Team): reimbursement and price decision No Does an application fulfil formal requirements? Yes Recommendation of AHTAPol (assessment and appraisal process) Submission of new therapeutical program NHF NHF (Drug Management Departament): final decision necessity to provide health care for the society making medicines accessible safety importance of a drug in a treatment of conditions associated with high epidemiological threat influence of a drug on direct medical costs affordability for the public payer obliged to finance healthcare services Positive decision Reimbursement list Positive decision New therapeutical program New criteria according to a new reimbursement law: still in development
2 Pricing Approval Process criteria Production cost (provided by the manufacturer) Cost of daily treatment Cost of standardized therapy Risk-benefit ratio compared to alternative pharmaceuticals for that indication Therapy costs per day in comparison to products with the same efficacy Evaluation of the economic impact on the national health system Estimated sales of the new pharmaceutical product Prices in countries with similar GDP New criteria according to a new reimbursement law: elaborated under twinning project, date of coming into force still to be agreed AHTAPol a new institution in reimbursement process Created in 2005 (Ordinance by MoH Sept 2005) Steps undertaken to prepare the Law on AHTAPol establishment The Bill prepared and submitted for Parliament work Planned to come into force in 2009 (July?) AHTAPol tasks and activities AHTAPol tasks and activities Still a lot of discussions International collaboration! EUnetHTA, INAHTA, HTAi, ISPOR, GIN, WHO/HEN, MEDEV Drug reimbursement list (Transparency Directive!) Therapeutic programmes Non drug technologies Assessment of analysis in terms of credibility and quality Clinical effectiveness Cost effectiveness Budget impact analysis Consultative Council (CC) the role CC recommendations all recommendations drugs-reimbursement list drugs-therapeutic programs non-drug technologies HTA in decision making process Assessment, Appraisal and Decision taking Completely separated processes Assessment (in most cases quality control/audit of industry s submission) by Analytic Team Appraisal/value judgement by Consultative Council (CC) CC recommendations (8 possible types) Decision taking/final decision by Minister of Health Reimbursement high-cost drugs by National Health Fund in Poland Therapeutical program: definite medical indication for described target population for 1 medical indication program can cover a few drug technologies particular patient population in programs are separate sets
3 Reasons for creation therapeutical programs medical needs for treatment with innovative technologies; inaccessibility of patients to high-cost, innovative drugs; impossibility of using reimbursement policy tools like the lists of reimbursed drugs, specified by separate regulations of the Minister of Health; necessity of application of uniform criteria for qualification of patients for a therapeutic program (equal access) and treatment with innovative technologies enabling to monitor related expenses of the payer special requirements for health care providers (relevant number of specialists or medical facilities etc.) Structure of therapeutical program Therapeutical program planned and intended actions of health care (financed from public means) considered as clinical effective, cost effective and with proven safety profile, enabling to satisfy health needs and improvement health status of health care beneficiaries in the prescribed time Therapeutic program is introduced for a specific clinical indication Rules of structure of therapeutic programs financed by the National Health Fund provide financing one or more health technologies Application of new program New technology or new program can apply: the Minister of Health the national consultant in the appropriate medical speciality the director of the HTA Agency Priority in implementation of therapeutic programs Priority is given to therapeutic programs related to: clinically most important health technologies (from social perspective) most cost-effective health technologies among options or alternatives; health technologies, which can be financed within resources allocated in the NHF financial plan for financing of therapeutic plans Therapeutical Programs 2008 examples: AHTAPol recommendation examples: TP name Disease name Active substance Disease name Recommendation Treatment of breast cancer Treatment of large intestine cancer Treatment of brain glioma Treatment of chronic granulocytic leukemia Treatment of gastrointestinal stromal tumor (GIST) Treatment of malignant lymphoma Treatment of essential thrombocytosis Treatment of precocious puberty in children Treatment of spasticity in poliomyelitis Treatment of primary immunodeficiencies in children Treatment of multiple sclerosis TRASTUZUMAB IRINOTEKAN // FLUOROURACIL // CALCII FOLINAS TEMOZOLOMID IMATINIB or DASATINIB IMATINIB RITUXIMAB ANAGRELID LEUPROLELINUM or TRIPTORELINUM BOTULINE TOXIN TYPE A IMMUNOGLOBULINA INTERFERON BETA or GLATIRAMER trastuzumab interferon beta glatiramer bosentan, iloprost, epoprostenol, sildenafil, treprostinil tobramycin (inhaled) alfa glukozydaza nilotynib lenalidomid etanercept, adalimumab, infliksimab, leflunomid abatacept Breast cancer Multiple sclerosis Multiple sclerosis Pulmonary arterial hypertension Pulmonary infection (chronic) - patients with cystic fibrosis Pompe disease Myeloid leukemia Myeloma Rheumatoid arthritis Rheumatoid arthritis + (temporary) 1th - ; 2nd conditional recommendation + sildenafil, bosentan, prostacyclin analogues + (TP) - (reimbursement list) + for 1 subpopulation + -
4 Initiate technology In case of two or more health technologies as options for the treatment in the same medical indication: 1) based on their assessment of efficacy made by the AHTAPol (with proven lack of significant differences in clinical effectiveness) 2) no reasons that makes it inadvisable to prescribe a particular drug in individual cases, - treatment should normally be initiated with the least expensive drug (taking into account administration costs, required dose and product price per dose). Challenges and future developments price volume agreements; risk sharing agreements (outcomes guarantee) - rejestry kliniczne; payback arrangements; value based pricing (UK solution) - flexible pricing; non - commercial trials Adverse effects financing and monitoring Implemention of adverse effects treatment financing in chemotherapy (3 rd, 4 th degree in accordance with CNI CTC) Implemention of precise monitoring in IT system (highcost adverse effects related to active substances) Unused drugs (resignation of utilization) Planned changes - Improvement of reportaccounting system Similar to registers effectiveness data and high-cost events Similar to clinical trials monitoring medical documentation vs NHF data Contract values for TP in and prognosis for 2009 Problems with reimbursement decision making of expensive (innovative) drugs TP [mill. PLN , , , plan 2009 plan High cost of clinical trials Lack of credible evidence of clinical efficacy and effectiveness: Small population of patients Short time of observation in clinical trials Lack of information about results of clinically important outcomes (desirable and undesirable ones) Programy terapeutycz
5 Cost effectiveness tresholds P O L A N D UK G E R M A N Y F R A N C E UK cost effectiveness PKB per capita x PKB per capita 2PKB per capita 2007* treshold PKB per capita 2007* PKB per capita 2007* AHTAPol challenges AHTAPol: limited human resources difficulties in recruiting new experienced staff in fact AHTAPol has been engaged in analytical process since 2007 necessity of continuous training Insufficient development of patient registries in Poland lack of epidemiological data PKB = GDP With accordance to the rate of exchange on 22nd of Nov. 2008) Highly cost-effective technologies Cost-effective technologies Lowly cost-effective technologies (?) * Source: Oxford Economics 1 QALY < PLN 1 QALY PL 1 QALY P Political issues: power of the mass media in several situations patient associations often financed by pharmaceutical companies Dilemma: where is The cost-effectiveness threshold? high costly drugs (ex. orphan drugs): what shall we do in case of iinsufficient evidence? Thank you for your attention Questions???» i.lipska@aotm.gov.pl» b.osinska@aotm.gov.pl
MEDEV COLLABORATION EU ASSESMENT FOR REIMBURSEMENT
EU-assessment for MEDEV reimbursement COLLABORATION EU ASSESMENT FOR REIMBURSEMENT Ad Schuurman Krakow November 25 2008 Some Figures Turnover in Europe: 150,000,000,000.- Investment pharma industry Marketing
More informationFirst Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA
More informationIndranil Bagchi, Ph.D. Vice President, Market Access Specialty Care, Pfizer CADTH SYMPOSIUM May 6, 2013
Characterizing the value of orphan drugs in an HTA environment Indranil Bagchi, Ph.D. Vice President, Market Access Specialty Care, Pfizer CADTH SYMPOSIUM May 6, 2013 Agenda Background Regulatory Approval
More informationDRUG PRICING IN ADRIATIC COUNTRIES IS REFERENCE PRICING THE BEST OPTION? CROATIAN EXPERIENCE
CROATIA The Ministry of Health of the Republic of Croatia is a state administration body and the most of its activities the Ministry carries out through: The Croatian Health Insurance Fund - CHIF (Hrvatski
More informationSpecialty medicine: Pearls from the PBMI conference, Scottsdale, Arizona Dr. Elsa Badenhorst
Specialty medicine: Pearls from the PBMI conference, Scottsdale, Arizona 2012 Dr. Elsa Badenhorst The Magic Bullet Paul Ehrlich (1854-1915) if a compound could be made that selectively targeted a diseasecausing
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationPFF DISEASE EDUCATION WEBINAR SERIES. Welcome!
PFF DISEASE EDUCATION WEBINAR SERIES Welcome! PFF DISEASE EDUCATION WEBINAR SERIES David J. Lederer, MD, MS PFF Senior Medical Advisor, Patient Communications Harold Collard, MD PFF Medical Advisory Board
More informationWhite paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act
White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationHTA methodology at HIQA. Conor Teljeur
HTA methodology at HIQA Conor Teljeur What is HTA? Health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related
More informationUse of immunotherapy for cancer treatment
Use of immunotherapy for cancer treatment Pre- and post-licensing considerations Professor Angela Thomas, Pediatric Hematologist Vice Chair Commission on Human Medicines Chair Clinical Trials, Biologicals
More informationDrug Spending % of Healthcare Spending DRUG SPENDING % OF HEALTHCARE SPENDING 20% 15% 10% 5% 0% 1995 2000 2005 2010 2015 Japan, 15.0% France, 9.8% US Net, 9.8% UK, 9.7% Germany, 9.0% France Germany Japan
More informationHigh cost medicines how to make them affordable Finnish perspective
Rational use of medicines within the social and healthcare system: effective use of research data August 21, 2018 High cost medicines how to make them affordable Finnish perspective Heikki Ruskoaho Division
More informationAMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA
News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone (805) 447-1000 Fax (805) 499-3507 www.amgen.com AMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION
More informationNew approaches to pricing & funding and implications for access: the BeNeLuxA Collaboration
New approaches to pricing & funding and implications for access: the BeNeLuxA Collaboration Diane Kleinermans Advisor to the Belgian Minister of Healthcare and Social Affairs 9th European Conference on
More informationStakeholder Consultation Strategy
Stakeholder Consultation Strategy Strengthening of the EU cooperation on Health Technology Assessment (HTA) 1. Context The present stakeholder consultation aims to provide broad and high quality information
More informationPolicy principles for a competitive healthcare environment
Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationHospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies
Sumant Ramachandra, MD, PhD SVP and Chief Scientific Officer Alliance for Health Reform May 20 th, 2015 Hospira at a glance The World s Leading Provider of Injectable Drugs and Infusion Technologies Market
More informationCouncilofthe EuropeanUnion Brussels,28October 2014 (OR.en)
ConseilUE Councilofthe EuropeanUnion Brussels,28October 2014 (OR.en) PUBLIC 14793/14 LIMITE PHARM81 SAN405 MI817 COMPET590 NOTE From: To: Subject: GeneralSecretariatoftheCouncil Delegations DraftCouncilconclusionsoninnovationforthebenefitofthepatients
More informationOrphan Medicinal Products
Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000
More informationHEALTH TECHNOLOGY ASSESSMENTS IN KOREA
HEALTH TECHNOLOGY ASSESSMENTS IN KOREA July 24, 2012 HTA and Coverage Decisions Conference Taipei, Taiwan Jeonghoon Ahn, PhD Senior Director National Evidence-based healthcare Collaborating Agency (NECA)
More informationThe Context in which we operate
Prof. Sergio Pecorelli Presidente Agenzia Italiana del Farmaco Rettore Università degli Studi di Brescia The Context in which we operate Limited Resources Population Ageing Healthcare rights One single
More informationAffordable and sustainable patient access to personalised medicine
Affordable and sustainable patient access to personalised medicine 1. The promise of personalised medicine Personalized medicine, or PM, promises to revolutionize healthcare, with its key goal of providing
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationOrphan Drug Designation within the Development Strategy
Case Report imedpub Journals http://wwwimedpub.com Journal of Rare Disorders: Diagnosis & Therapy Vol. 1 No. 2:12 DOI: 10.21767/2380-7245.100012 Orphan Drug Designation within the Development Strategy
More informationIT S WHAT YOU CAN T SEE THAT HURTS YOU IS THE PHARMACEUTICAL INDUSTRY REPLACING EXISTING MEDICATIONS WITH MORE EXPENSIVE MEDICATIONS?
SPECIALTY DRUGS Many plan sponsors have had to make difficult and painful choices about how to spend pharmacy benefit dollars But now payors are once again challenged not just by extremely high costs but
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Erythropoiesis Stimulating Agents (ESAs) Reference Number: TCHP.PHAR.1813 Effective Date: 07.01.18 Last Review Date: 04.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder
More informationAccess to and reimbursement for diagnosis and therapy. Tumor vaccination for brain cancer Barriers, hurdles, problems, threats, challenges
Access to and reimbursement for diagnosis and therapy Tumor vaccination for brain cancer Barriers, hurdles, problems, threats, challenges Medicinal products for orphan diseases Stefaan Van Gool No conflict
More informationICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada
ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada Anthony Ridgway, Ph.D. Senior Regulatory Scientist Biologics & Genetic Therapies Directorate Health Canada Open
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationEarly access or speed kills? A payer s perspective
Dürfen lebenswichtige Medikamente Early access or speed kills? A payer s perspective Health as the real winner: Presidency Conference on Options to Provide Better Medicines for All Sofia,06.03.2018, Director
More informationOverview of health care system in Japan
ISPOR Asia Pacific 2018, Tokyo, Japan 10 September 2018 W5: Japanese HTA and Pricing: Current Methods and Future Potential Introduction of Japanese Pricing System Makoto Kobayashi, MEng, PhD Director and
More information6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels
www.eurordis.org 6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels Brussels, 24-25 May 2012 www.eurordis.org THE NEW PARADIGMS OF RARE DISEASES TREATMENT DEVELOPMENT & ACCESS
More informationImportance of Research on Rare Diseases and Orphan Drugs
Importance of Research on Rare Diseases and Orphan Drugs Introduction There are significant moral, scientific, economic and policy imperatives for conducting research into rare diseases. A rare disease
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationEuropean perspectives: Real world outcome needs of payers, current and anticipated
European perspectives: Real world outcome needs of payers, current and anticipated ISCTM Washington DC, Feb 20, 2019 Emma Medin, MD, MSc Vice President, PAREXEL International Disclosure slide Emma Medin
More informationMARCH Express Scripts 2015 Drug Trend Report Executive Summary
MARCH 2016 Express Scripts 2015 Drug Trend Report Executive Summary Together we brought down out-of-pocket costs for patients and slowed the increase in U.S. drug spend. G oing into 2015, healthcare payers
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationSpecialty Pharmacy 101
Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current
More informationPaying for value: international developments
Paying for value: international developments Kalipso Chalkidou NICE (UK) Harkness Fellow CMTP and Johns Hopkins School of Public Health UK developments in drug pricing We recommend that Government reform
More informationBiosimilars are interchangeable with their reference products under the supervision of a health care person.
EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES? Tomas Tesar, PharmD, PhD, MBA, MSc Member of
More informationHigh Cost Drugs Clinical Coding Standards and Guidance OPCS-4
High Cost Drugs Clinical Coding Standards and Guidance OPCS-4 Clinical Classifications Service Date 6 th March 2014 1 Copyright 2014, Health and Social Care Information Centre. Contents Introduction...
More informationPATIENT GROUPS & CLINICAL TRIALS CASE STUDY
February 1, 2017 PATIENT GROUPS & CLINICAL TRIALS CASE STUDY Jeffrey W. Sherman, M.D., FACP Past President Inaugural Fellow Chief Medical Officer Executive Vice President Disclaimer The views and opinions
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More information1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European
More informationCommission's proposal to review EU pharmaceutical legislation
SPEECH/01/354 Mr Erkki Liikanen Member of the European Commission, responsible for Enterprise and the Information Society Commission's proposal to review EU pharmaceutical legislation Press conference
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationLooking beyond ICH-E9 in the Era of Global Drug Development
Biostatistics Summer Workshop 2012 Looking beyond ICH-E9 in the Era of Global Drug Development Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency This is not an official
More informationHEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE
HEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE NATASHA KEKRE, MD, MPH, FRCPC NOV 16, 2016 www.ohri.ca WHY THIS MATTERS TO ME I am a hematologist in Ottawa with 75% dedicated time for research
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationENCEPP CONSIDERATIONS ON THE DEFINITION OF NON-INTERVENTIONAL TRIALS UNDER THE CURRENT LEGISLATIVE FRAMEWORK ( CLINICAL TRIALS DIRECTIVE 2001/20/EC)
ENCEPP CONSIDERATIONS ON THE DEFINITION OF NON-INTERVENTIONAL TRIALS UNDER THE CURRENT LEGISLATIVE FRAMEWORK ( CLINICAL TRIALS DIRECTIVE 2001/20/EC) Agreed by the European Network of Centres for Pharmacoepidemiology
More informationCorporate Presentation
Corporate Presentation December 2015 Half Year 2017 Business and Financial Update Webcast Presentation, 19 th September 2017 Eduardo Bravo, Chief Executive Officer Claudia D Augusta, Chief Financial Officer
More informationEMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA
EMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA Slides largely re-produced from a previous EMA presentations to (DIA, Paris; STAMP, Brussels).
More informationScottish Medicines Consortium
Scottish Medicines Consortium interferon alfa 2b (Viraferon and Intron A* ) 18 million IU, solution for injection, multidose pen in combination with ribavirin (Rebetol ) capsules 200 mg No. (258/06) Schering
More informationReimbursement Overview. Michael Barry
Reimbursement Overview Michael Barry September 2017 The NCPE has moved Access to medicines media and public awareness 9/12/2016 2/9/2011 1/6/2016 21/1/2013 Millions ( ) Total expenditure on medicines approximately
More informationDelivery /Replenishment strategies used as Supply Chain practice A supplier view
Delivery /Replenishment strategies used as Supply Chain practice A supplier view Dr. Michael Heerde Director Healthcare Programs Bayer AG Page 1 Forward-Looking Statements This presentation may contain
More informationCurrent Status and Perspectives of Placebo-controlled Studies
Provisional Translation (as of June 1, 2016) March 9, 2016 Current Status and Perspectives of Placebo-controlled Studies Subcommittee on Placebo-controlled Studies Kazuhiko Yamamoto, Chairperson Yoshihiro
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationClinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Kymriah) Reference Number: CP.CPA.XX Effective Date: 09.26.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationEconomic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with
Economic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. January 2012 Telaprevir Summary 1.
More informationCADTH s Proposed Process for the Assessment of Companion Diagnostics
CADTH s Proposed Process for the Assessment of Companion Diagnostics 1. Preamble Companion diagnostics identify subgroups of patients for whom select drugs are likely to be most effective and safe. Based
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationDefining the true market
Defining the true market Case study: How real-world data and outcomes improved a major pharmaceutical company s launch strategy Cardinal Health Specialty Solutions Competing in a crowded marketplace A
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationVALUE ADDED MEDICINES. Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University
VALUE ADDED MEDICINES Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University What Are Value Added Medicines? Value added medicines are defined as medicines based on known molecules that
More informationPublished 07 February 2011 Page January 2011
filgrastim 12 million units (120microgram) / 0.2mL, 30 million units (300microgram) / 0.5mL, 48 million units (480microgram) / 0.5mL solution for injection/infusion in pre-filled syringe (Nivestim) SMC
More informationBi Regional Consultation on Good Governance
Pharmaceutical Services Ministry of Health Malaysia GGM PROGRAMME IN MALAYSIA WHO Collaborating Centre For Regulatory Control of Pharmaceuticals Bi Regional Consultation on Good Governance 9 th November
More informationRepurposing a medicine
Repurposing a medicine Sub-session 2 of Parallel Session 8 - New medicines and medical technologies, clinical trials and stakeholders support 4th Conference on European Reference Networks 21 22 November
More informationMedicines Control Council & update on SA Health Products Regulatory Authority
Medicines Control Council & update on SA Health Products Regulatory Authority South African Pharmaceutical Regulatory Affairs Association (SAPRAA) 08 April 2016 Outline Introduction Policy & Legislative
More informationUnderstanding clinical research trials
Understanding clinical research trials Dr. Isabelle Fleury Medical Hemato-oncologist Hôpital Maisonneuve-Rosemont CIUSSS de l Est-de-l Île-de-Montréal Goals of this presentation Better understand clinical
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationA Guide to Specialty Drugs for Employers. Overview. Sue Heineman, PharmD, BCPS National Employer Medical Outcomes Specialist Pfizer Inc.
A Guide to Specialty Drugs for Employers Sue Heineman, PharmD, BCPS National Employer Medical Outcomes Specialist Pfizer Inc. 10/12/2016 1 A Guide to Specialty Drugs for Employers: of specialty drugs of
More information8 th STAMP expert group meeting
8 th STAMP expert group meeting Repurposing: Themes & discussion points from case studies Dr Daniel O Connor MHRA (UK) Repurposing medicines Drug repurposing is the process of identifying a new use for
More informationSolving the Problem of New Uses
Solving the Problem of New Uses Benjamin Roin, Harvard Law School benroin@law.harvard.edu Presented at Duke Law School Center for Innovation Policy s New Approaches and Incentives in Drug Development,
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationIssues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007
Issues in Cancer Drug Development of the Future Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Agenda: Scientific Issues n Why improve the quality of cancer clinical
More informationClinical Policy: Sargramostim (Leukine) Reference Number: CP.CPA.262 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Leukine) Reference Number: CP.CPA.262 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research
ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research Pascale Boyer Barresi, CFA Business Analysis, BD&L September 2014
More informationThe Mochida Pharmaceutical Group s Medium Term Management Plan
The Mochida Pharmaceutical Group s 17-19 Medium Term Management Plan This material is an English translation of the press release issued on April 3, 2017 in Japanese, and the Japanese release is given
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationPHARMACEUTICAL PRICING & REIMBURSEMENT SYSTEM IN SPAIN
PHARMACEUTICAL PRICING & REIMBURSEMENT SYSTEM IN SPAIN PPRI Conference 29-30 September 2011, Vienna Piedad Ferré Pharmaceutical offer in Spain some features High coverage and rapid accessibility Pharmaceutical
More informationUse of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL PUBLIC CONSULTATION
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Healthcare systems Health systems and products PUBLIC CONSULTATION Brussels, 31 July 2012 on the modalities of stakeholder consultation in the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationBiologicals & biosimilars; addressing the needs of patients and payers. The Role of Functioning Competitive Markets
Biologicals & biosimilars; addressing the needs of patients and payers The Role of Functioning Competitive Markets Agenda Why do patients and payers need biosimilars? How can we increase the uptake of
More informationWhen and how to implement biomarker for cancer care from a French perspective. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
When and how to implement biomarker for cancer care from a French perspective Fabrice ANDRE Institut Gustave Roussy Villejuif, France Outline Levels of evidence before implementing a biomarker to the daily
More informationBIOPHARMACEUTICAL BUSINESSES
BIOPHARMACEUTICAL BUSINESSES Our Biopharmaceuticals businesses consist of four patientcentric, customer-facing business units. The business units are responsible for further clinical development and lifecycle
More informationDevelopment of a new medicinal product. as. MUDr. Martin Votava, PhD.
Development of a new medicinal product as. MUDr. Martin Votava, PhD. Development and registration of a medicinal product Costs of development: 800 mil USD Time to develop: 10 years Successfulness: 0,005%
More informationTHE BIOPHARMA DILEMMA:
THE BIOPHARMA DILEMMA: Balancing Innovation and Affordability Amitabh Chandra HARVARD UNIVERSITY Disclosures Panel of Health Advisors, CBO Speaking fees from Biogen, Novo Nordisk, Pfizer, PCMA, Roche Consultant
More informationEthical approaches to Innovation in Global Health
Georg Marckmann Institute of Ethics, History and Theory of Medicine Ethical approaches to Innovation in Global Health World Health Summit Satellite Event Innovation in Health: The contribution of biologic
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationEconomic evaluations in cancer clinical trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More information